

PBL

Application of Biochemistry in dental practice

Talib A. Najjar , DMD, MDS, PhD
Professor Oral & Maxillofacial Surgery
Rutgers University

Biochemistry Interaction with Oral & Systemic Diseases

Periodontal disease
Jaw Bone Necrosis
due to Bisphosphonate

Paget`s Disease
Osteoporosis

pathogenesis of Patient Condition
presented with:

Osteonecrosis of the jaw
bone due to
Bisphosphonate

Patient's Data

- 54 year old male presented with sever **periodontal** disease ,type 2 diabetes ,lung **cancer** treated with **Bisphosphonate**







Progress of Dental Treatment

Patient referred to his Dentist for oral evaluation during cancer therapy.

Dentist referred him to Periodontist to evaluate periodontal condition.

Periodontist referred him to Oral Surgeon. Oral Surgeon performed for full mouth extractions due to severe periodontal condition.

This leads to severe **osteonecrosis** of the maxillary and mandibular alveolar ridges





Biochemistry Knowledge Provide Better Understanding of this patient

Osteonecrosis of jaw
bone due to
Bisphosphonate

Why Bisphosphonate causes such a severe Osteonecrosis & Why it was used ?

Why Bisphosphonate was given to this patient ?

-
- Bisphosphonate (Aredia or Zometa[®]) are used to control

Bone metastases from lung cancer

Hypercalcemia due to bone metastasis

Common uses of Bisphosphonate

Oral Forms

- Prevention and treatment of osteoporosis in postmenopausal women
- Increase bone mass in men with osteoporosis
- Glucocorticoid-induced osteoporosis
- Paget's disease of bone
- osteogenesis imperfecta


Intra-venous Forms

- Hypercalcemia of malignancy
- Bone metastases of solid tumors
- Breast and prostate carcinoma; other solid tumors
- Osteolytic lesions of multiple myeloma


Relative Potency & Effect of Bisphosphonates

• Etidronate (Didronel)	1
• Tiludronate (Skelide)	10
• Pamidronate (Aredia)	100
• Alendronate (Fosamax)	1,000
• Risedronate (Actonel)	10,000
• Ibandronate (Boniva)	10,000
• Zolendronic acid (Zometa)	>100,000

US Surgeon General Report recommends a pyramidal approach to osteoporosis treatment




Osteoporosis & Fracture Risk



Paget's Disease









Paget's Diseases

- Characterizes by increased bone mass & density
- Abnormal bone remodeling
- Enlarged head and jaw bones
- Patient frequently change hat ,eyeglasses and dentures
- Cotton-wool appearance in the radiograph
- Loss of sight and hearing
- High Alkaline Phosphatase

Bisphosphonate therapy for Paget's disease





•Rendina et al. NEJM 353:24, 2005

Bisphosphonate

Basic Chemical Composition


- **Pyrophosphate compound**
Essential for normal cellular functioning as it incorporate in ATP
- **Substitution of Carbon for Oxygen**
Resistance to hydrolysis
Bone matrix accumulation
Extremely long half-life
- **Nitrogen-containing side chain**
Increases potency, toxicity
Direct link to BIONJ cases



Chemical Structure


Pyrophosphate (PPi)

(ATP = AMP + PPi)




Bisphosphonate

(P-C-P)





P-C-P acts as
'bone hook'
and is essential
for binding to
hydroxyapatite



When R¹ is an OH
group binding to
hydroxyapatite
is enhanced

The R2 side
chain determines
potency

The P-C-P group
is essential
for biological activity

Bisphosphonate Structure



Nitrogen Side Chain


Alendronate (Fosamax)

Risedronate (Actonel)

Ibandronate (Bonviva)

Zolendronate (Zometa)

Pamidronate (Aredia)



Non Nitrogen Side Chain

Etidronate (Didronel)

Clondronate (Bonefos)

Tiludronate (Skelid)

Bisphosphonate Structure

Understanding Pathogenesis of Bone Necrosis



Understanding the pathophysiology of Bone Remodeling



Bone remodeling as Tissue Organ & System

Tissue

Haversian (osteons) which are aligned to withstand biofunctional challenges


Organ

Mandible

Tibia


System

Interact with endocrine, renal, vascular & GI systems




Effects of other systems in Bone Remodeling

Endocrine System




Bloodstream maintains a constant concentration of Ca^{++}

$\uparrow \text{Ca}^{++}$
Kidneys conserve Ca^{++}



$\uparrow \text{Ca}^{++}$
Intestine absorbs Ca^{++} from diet



Understanding Pathogenesis of Bone Necrosis





Biochemistry of Bisphosphonate

**Inhibition of farnesyl
diphosphate synthase in the
osteoclasts**

**Metabolized to toxic analogue
of ATP (non-nitrogen
containing Bisphosphonate)**

Bisphosphonate Causes The Following

1. Disruption of normal bone turnover
2. Compromised bone blood flow
3. Antiangiogenic
4. Mucosal toxicity
5. Local Environments of the Oral Cavity

Bisphosphonate

Pharmacokinetics

Rapid accumulation in sites of increased bone deposition


Not metabolized (nitrogenous)

Repeated doses accumulate in bone

Bone $\frac{1}{2}$ life of “years” – maybe a lifetime..


Removed only by osteoclast-mediated resorption

“Biologic Catch 22”




Bone resorption


Bone formation




Normal Bone Remodelling



Bc



Cellular Mechanism of Action



1. Osteoclast actively reabsorbs bone matrix
2. BISPHOSPHONATE (☀) binds to bone mineral surface
3. BISPHOSPHONATE is taken up by the osteoclast
4. Osteoclast is inactivated
5. Osteoclast becomes apoptotic ('suicidal') and dies

Biologic Action of Bisphosphonates

- Osteoclastic toxicity

Apoptosis

Inhibited release of bone
induction proteins

BMP, ILG₁, ILG₂



Reduced bone turnover,
resorption

Reduced serum calcium*

Hypermineralization

*

“sclerotic” changes in
lamina dura of
alveolar bone




Bisphosphonates Effects on Osteoclasts

Bisphosphonate attaches to exposed bone mineral surfaces

Osteoclast takes up bisphosphonate → loss of ruffled border, inactivation, detachment

New bone formation by osteoblasts renders bisphosphonate inert, inaccessible



 Lining cells

 Osteoclast precursors

 Inactivated osteoclast

 Bisphosphonate

 Osteoclast

 Osteoblast

1. Sato M et al. *J Clin Invest.* 1991;88:2095–2105.

2. Rodan G et al. *Curr Med Res Opin.* 2004;20:1291–1300.

contributes to his sever osteonecrosis ?

- Does hyperglycemia (increased blood sugar) alone influenced his osteonecrosis ?
- Does abnormal metabolic changes in the glucose and ultimately protein and lipid metabolisms influenced his osteonecrosis ?

Conclusion

- In this patient the combination of hyperglycemia , ketoacidosis , Steroid , Bisphosphonate ,chemotherapy and his lung cancer resulted in reduce blood supply ,impaired tissue function and reduced vascularity which resulted in sever periodontal disease . Osteonecrosis subsequent to teeth extractions were due to IV bisphosphonate use.